De-Escalation of Dual Antiplatelet Therapy With Ticagrelor and Aspirin in Non-disabling Non-cardioembolic Ischemic Stroke or High Risk TIA Patients: A Randomized, Outcome Assessor Blind, Controlled Trial

This is a randomized, controlled, outcome assessor blind, parallel group design pilot study on 100 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina Hospital, Sari,Iran.The aim of study is to compare the efficacy of 90 mg ticagrelor BID plus aspirin for 1 month and 60 mg ticagrelor BID plus aspirin for 3 months in reduce of non-disabling non-cardioembolic ischemic stroke or high risk TIA recurrence during first 12 months.

Start Date01 Dec 2024

Sponsor / Collaborator

Mazandaran University of Medical Sciences

IRCT20090613002027N23 / SuspendedPhase 2/3IIT

Evaluation of the safety and efficacy of megestrol acetate plus mirtazapine in combination versus megestrol acetate alone in cachexia induced by GI cancers

Start Date22 Oct 2024

Sponsor / Collaborator

Mazandaran University of Medical Sciences

IRCT20090613002027N22 / RecruitingPhase 2/3IIT

Comparison the efficacy and safety of mirtazapine and olanzapine in prevention of nausea and vomiting following highly emetogenic chemotherapy; a double blinded, randomized crossover clinical trial

Start Date01 Oct 2024

Sponsor / Collaborator

Mazandaran University of Medical Sciences

100 Clinical Results associated with Mazandaran University of Medical Sciences

0 Patents (Medical) associated with Mazandaran University of Medical Sciences

10,367

Literatures (Medical) associated with Mazandaran University of Medical Sciences

01 Jul 2025·Current Nanomedicine

Nanoencapsulation of Colchicum speciosum for Alleviating Lower Back Pain

Author: Kiabi, Farshad Hassanzadeh ; Beiranvand, Siavash

Abstract:This review focuses on the use of Colchicum species that have been capsuled to treat lower back pain. Low levels of physical activity produce atypical spinal loading, which increases the risk of discomfort and damage. Acetylcholine (AChE inhibitors acetylcholinesterase AChE-I) has a crucial role in the development of amyloid- plaques, one of the disease's main pathogenic processes, and in boosting psychological function. To increase the natural preservatives in food, research on the encapsulation of phytochemicals has been employed to create nanoparticle delivery systems for a combination of terpenes that have been isolated from plants. For the administration of formulations containing encapsulated plant extracts, dermal and oral routes are used. The current strategies of encapsulation should be enhanced, as well as techniques to achieve the goal.

01 Feb 2025·Non-coding RNA Research

Emerging roles of non-coding RNAs in modulating the PI3K/Akt pathway in cancer

Review

Author: Habibi, Fatemeh ; Asadi, Saba ; Taheri, Elham ; Khorrami, Ramin ; Hashemi, Mehrdad ; Rahimzadeh, Payman ; Taheriazam, Afshin ; Nabavi, Noushin ; Vazayefi, Paria ; Shekarriz, Helya ; Abdolmohammad Sagha, Ramina ; Tanha, Mahsa ; Ghatei Mohseni, Forough ; Rashidi, Mohsen ; Mortazi, Shaghayegh ; Entezari, Maliheh ; Mohandesi Khosroshahi, Elaheh

Cancer progression results from the dysregulation of molecular pathways, each with unique features that can either promote or inhibit tumor growth. The complexity of carcinogenesis makes it challenging for researchers to target all pathways in cancer therapy, emphasizing the importance of focusing on specific pathways for targeted treatment. One such pathway is the PI3K/Akt pathway, which is often overexpressed in cancer. As tumor cells progress, the expression of PI3K/Akt increases, further driving cancer advancement. This study aims to explore how ncRNAs regulate the expression of PI3K/Akt. NcRNAs are found in both the cytoplasm and nucleus, and their functions vary depending on their location. They can bind to the promoters of PI3K or Akt, either reducing or increasing their expression, thus influencing tumorigenesis. The ncRNA/PI3K/Akt axis plays a crucial role in determining cell proliferation, metastasis, epithelial-mesenchymal transition (EMT), and even chemoresistance and radioresistance in human cancers. Anti-tumor compounds can target ncRNAs to modulate the PI3K/Akt axis. Moreover, ncRNAs can regulate the PI3K/Akt pathway both directly and indirectly.

01 Feb 2025·Current Gene Therapy

Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Review

Author: Mousavi, Tahoora ; Alimohammadi, Mina ; Araghi, Mahmood ; Soleimantabar, Hussein ; Mafi, Alireza ; Gharebakhshi, Farshad ; Faramarzi, Fatemeh

Background:Metastatic Triple-negative Breast Cancer (mTNBC) is the most aggressive form of breast cancer, with a greater risk of metastasis and recurrence. Research studies have published in-depth analyses of the advantages and disadvantages of pembrolizumab, and early data from numerous trials suggests that patients with mTNBC have had remarkable outcomes. This meta-analysis compares the data from numerous relevant studies in order to evaluate the safety and efficacy of pembrolizumab monotherapy or combination therapies for mTNBC.Methods:To identify eligible RCTs, a thorough literature search was carried out using electronic databases. CMA software was utilized to perform heterogeneity tests using fixed and random-effects models.Results:According to our pooled data, the median Progression-free Survival (PFS) was 2.66 months, and the median overall survival (OS) was 12.26 months. Furthermore, by comparing efficacy indicators between PD-L1–positive and PD-L1–negative groups, a correlation was found between the overexpression of PD-L1 with OS, PFS, and ORR. Patients with PD-L1-positive tumors had a higher response rate, with an ORR of 21.1%, compared to the patients with PD-L1-negative tumors. The ORR for first-line immunotherapy was higher than that of ≥second-line immunotherapy. In addition, pembrolizumab plus combination treatment resulted in a pooled incidence of immune- related adverse events of 22.7%.Conclusion:A modest response to pembrolizumab monotherapy was detected in the mTNBC patients. Furthermore, a better outcome from pembrolizumab treatment may be predicted by PD-L1-- positive status, non-liver/lung metastases, combination therapy, and first-line immunotherapy. Pembrolizumab, in combination with chemotherapy, may be more beneficial for patients whose tumors are PD-L1 positive.

100 Deals associated with Mazandaran University of Medical Sciences

100 Translational Medicine associated with Mazandaran University of Medical Sciences

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 24 Dec 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Mazandaran University of Medical Sciences

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 24 Dec 2024

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing